Spero Therapeutics Inc(SPRO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 10.26 | EPS (ttm) | 0.11 | Insider Own | 26.34% | Shs Outstand | 58.1M | Perf Week | -8.2% |
| Market Cap | 0.07B | Forward P/E | 1.67 | EPS next Y | 331.03% | Insider Trans | -0.16% | Shs Float | 42.9M | Perf Month | -8.94% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 15.81% | Short Float | 3.37% | Perf Quarter | -55.91% |
| Income | 0.01B | P/S | 1.52 | EPS this Y | -293.33% | Inst Trans | 1.79% | Short Ratio | 0.98 | Perf Half Y | -56.76% |
| Sales | 0.04B | P/B | 1.47 | EPS next 5Y | - | ROA | 12.85% | Short Interest | 1.45M | Perf YTD | -51.93% |
| Book/sh | 0.76 | P/C | 1.28 | EPS past 3/5Y | - | ROE | 19.17% | 52W High | -63.64% ($3.08) | Perf Year | -42.27% |
| Cash/sh | 0.87 | P/FCF | 3.33 | Sales past 3/5Y | 7.06% 197% | ROIC | 16.69% | 52W Low | 3.7% ($1.08) | Perf 3Y | -17.65% |
| Dividend Est. | - | EV/EBITDA | 6.39 | EPS Y/Y TTM | 114.38% | Gross Margin | - | Volatility(W/M) | 2.91% 3.77% | Perf 5Y | -93.89% |
| Dividend TTM | - | EV/Sales | 0.38 | Sales Y/Y TTM | 26.04% | Oper. Margin | 6% | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.12 | EPS Q/Q | -443.89% | Profit Margin | 17.18% | RSI (14) | 29 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.12 | Sales Q/Q | -100% | SMA20 | -7.23% ($1.21) | Beta | 1.5 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/12 | SMA50 | -20.26% ($1.4) | Rel Volume | 0.39 | Prev Close | $1.17 |
| Employees | 25 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -49.04% ($2.2) | Avg Volume(3M) | 1.47M | Price | $1.12 |
| IPO | 2017/11/2 | Option/Short | Yes/Yes | Trades | 882 | Volume | 568,390 | Change | -4.27% |
Company
SPRO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Spero Therapeutics is a US-based, clinical-stage biopharmaceutical company developing novel antibiotics to combat multi-drug-resistant infectious diseases. Its portfolio includes oral carbapenem-class antibiotics and other candidate compounds targeting gram-negative and non-tuberculous mycobacterial (NTM) infections. Through collaborations with major pharmaceutical companies, the company is expanding its pipeline in the antibacterial field, where there is significant unmet medical need.
Over the past 1 year, on the lower side
64% below its 1-year high.
SPRO makes money exceptionally well
6% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -293.3% this year.
Tap to view numbers
The stock looks undervalued
Trading at 10.3 times earnings.
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -17.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 15.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
QQQS 0.01%
IWC 0.00%
DFAS 0.00%
PRFZ 0.00%
VTI 0.00%It ranks #4 in the industry
Based on market cap of $65M.
SPRO $65M PER 10.3
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is SPRO?
SPRO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SPRO?
The market cap of SPRO is approximately $65M, ranking 4,813 within its sector.
What is the P/E ratio of SPRO?
SPRO has a P/E ratio of approximately 10.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SPRO?
SPRO has recorded a 52-week high of $3.08 and a low of $1.08.
